Sharon Rosenzweig-Lipson

TL;DR: The results of this study provide specific behavioral and autonomic evidence of anxiolytic-like effects for oxytocin in males and suggest the potential utility of OTR agonism as a therapeutically relevant mechanism of action for novel anxIOlytics in both sexes.

TL;DR: The present review addresses the most exciting approaches in the treatment of depression with selective serotonin reuptake inhibitors and reviews the localization, neurochemical and behavioral data that provide the supporting rationale for each of these targets or target combinations.

TL;DR: Elevations in IL-6 may have a pathophysiological role underlying depression and more specifically resistance to current classes of antidepressant medications and modulation of the IL- 6 signaling pathway may have therapeutic potential for treatment-resistant depression.

TL;DR: The pharmacological and neurochemical characterization of two novel and selective 5-HT6 receptor agonists reveal a potential therapeutic role for this receptor in the treatment of some types of anxiety-related disorders (eg OCD) and highlight a previously undescribed role for 5- HT6 receptors to modulate basal GABA and stimulated glutamate transmission.

TL;DR: The results suggest that diverse pharmacologic and somatic antidepressant treatments, as well as antipsychotics, increase levels of BDNF protein in the frontal cortex, even though they have different mechanisms of action at neurotransmitter systems.